Search

Displaying results 9611 - 9620 of 10000 in total
  1. Drug

    Adakitug

    go.drugbank.com/drugs/DB05484
    Investigational

    Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. … HuMax-Inflam was also effective in reducing disease activity in palmoplantar pustulosis patients in a clinical study.

  2. Drug

    ADH-1

    go.drugbank.com/drugs/DB05485
    Investigational

    ADH-1 may have utility in a wide variety of cancers as N-cadherin is overexpressed in a variety of tumors. … ADH-1 is currently in clinical development in a combination program with a range of chemotherapeutic agents to investigate the synergistic effects noted in our preclinical models.

    Synonyms: l-cysteinamide, n-acetyl-l-cysteinyl-l-histidyl-l-alanyl-l-valyl-, cyclic (1-5)-disulfide, Cys-His-Ala-Val-Cys
  3. Drug

    ATN-161

    go.drugbank.com/drugs/DB05491
    Investigational

    expected to extend to a variety of cancers. … ATN-161 is a non-RGD based integrin binding peptide targeting alpha-5 beta-1 and alpha-v beta-3.

  4. Drug

    Elacytarabine

    go.drugbank.com/drugs/DB05494
    Investigational

    Elacytarabine is a fatty acid derivative of [cytarabine], an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. … Elacytarabine is a patented new chemical entity of the nucleoside analog class, with improved biological properties and the potential to treat solid tumours such as non-small cell lung cancer, malignant

  5. Drug

    TAK-428

    go.drugbank.com/drugs/DB05499
    Experimental

    TAK-428 is a drug for treating diabetic neuropathy.

  6. Drug

    PI-0824

    go.drugbank.com/drugs/DB05516
    Investigational

    Peptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824.

  7. Drug

    CPG 10101

    go.drugbank.com/drugs/DB05530
    Investigational

    CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. … It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.

  8. Drug

    Ostabolin-C

    go.drugbank.com/drugs/DB05536
    Investigational

    Ostabolin C was under investigation in clinical trial NCT00787358 (A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT

    Synonyms: -GLUTAMYL-L-ISOLEUCYL-L-GLUTAMINYL-L-LEUCYL-L-METHIONYL-L-HISTIDYL-L-ASPARAGINYL-L-LEUCYLGLYCYL-L-LYSYL-L-HISTIDYL-L-LEUCYL-L-ASPARAGINYL-L-SERYL-L-METHIONYL-L-.ALPHA., L-VALINAMIDE, L-SERYL-L-VALYL-L-SERYL-L-.ALPHA.
  9. Drug

    AVI-4065

    go.drugbank.com/drugs/DB05620
    Investigational

    AVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc.

  10. Drug

    Palifosfamide

    go.drugbank.com/drugs/DB05668
    Investigational

    Palifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.